Enzymatic Production Of A Protein Or Polypeptide (e.g., Enzymatic Hydrolysis, Etc.) Patents (Class 435/68.1)
  • Patent number: 12279637
    Abstract: Aspects of the present disclosure relate to compositions having rice bran extract, method of making rice bran extract and method of using same.
    Type: Grant
    Filed: September 19, 2023
    Date of Patent: April 22, 2025
    Assignee: Florida Food Products, LLC
    Inventors: Pavan Kumar Soma, Peter VanAlstyne
  • Patent number: 12275789
    Abstract: The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2).
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: April 15, 2025
    Assignee: NBE-Therapeutics AG
    Inventors: Ulf Grawunder, Roger Beerli, Ina Hellmann, Lorenz Waldmeier
  • Patent number: 12262722
    Abstract: This disclosure describes methods to separate solids from liquids in a production facility. A process separates components in the process stream by applying non-condensable media to create density differences and then using a mechanical device to separate the solids from the liquids based on the density difference. The process produces the liquids and solids, which may be further processed to create valuable animal feed products.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: April 1, 2025
    Assignee: ICM, Inc.
    Inventors: Charles C. Gallop, Christopher Riley William Gerken, Jesse Spooner, Brandon Emme
  • Patent number: 12257298
    Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: March 25, 2025
    Assignee: ACADEMIA SINICA
    Inventors: Che Ma, Chi-Huey Wong, Han-Yi Huang
  • Patent number: 12234279
    Abstract: There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: February 25, 2025
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts
  • Patent number: 12181455
    Abstract: A method for analyzing spectra comprises identifying a set of sample peaks in a sample spectrum, where the sample peaks are associated with fragments of a sample, each having a sample fragment mass. A reference spectrum is selected with one or more reference peaks corresponding to fragments of a reference, each having a reference fragment mass. A mass difference can be determined between selected sample and reference peaks, and a group exchange can be selected based on the mass difference; e.g., where the group exchange represents a change in the sample or reference fragment masses associated with the selected peaks. The selected peaks can be shifted by the mass difference, and a fit value can be determined with respect to the reference spectrum. The fit value characterizes similarity between the respective sets of sample and reference peaks, responsive to the group exchange and corresponding peak shift.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: December 31, 2024
    Assignee: John Wiley & Sons, Inc.
    Inventors: Karl Nedwed, Michelle D'Souza, Ty Abshear
  • Patent number: 12163282
    Abstract: The present invention provides a powder-assembled composite micro-nano fiber and a method for preparing the powder-assembled composite micro-nano fiber. The method includes the following steps: (1) preparing two-dimensional cellulose from a cellulose-raw-material; (2) dispersing the two-dimensional cellulose and a powder material in a solvent to form a mixed suspension; and (3) performing freeze drying on the mixed suspension to obtain the powder-assembled composite micro-nano fiber, wherein a temperature difference between two ends in a vertical direction of the mixed suspension is controlled to be 10-100° C. in a freezing process of the freeze drying. In the present invention, a new non-destructive processing path from primary particles to macro applications is constructed, and rich material platforms and infinite possibilities are provided for basic studies and technical applications.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 10, 2024
    Assignee: ZHEJIANG A & F UNIVERSITY
    Inventors: Hanwei Wang, Qingfeng Sun, Chao Wang, Yingying Li
  • Patent number: 12137705
    Abstract: A pet food that comprises a soybean protein isolate, a fermented soybean meal or a mixture thereof wherein a content of ?-conglycinin is 5 mass % to 10 mass % in terms of dry matter, a content of a plant-based protein other than a plant-based protein derived from the soybean protein isolate and the fermented soybean meal is 11.0 mass % or less in terms of dry matter, and digestibility of a protein contained in the pet food is 88% or more.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: November 12, 2024
    Assignee: UNICHARM CORPORATION
    Inventors: Junya Sakoda, Fumisato Yoshiga
  • Patent number: 12137704
    Abstract: A composition and method of preparing a pea protein hydrolysate includes obtaining a pea protein composition, adding a fungal protease to the pea protein composition, and hydrolyzing the pea protein composition to a degree of hydrolysis of about 4% or greater to obtain a pea protein hydrolysate. In an example, the degree of hydrolysis can range from about 4% to about 25% at a pH ranging from about 5 to about 7.5 and at a temperature ranging from about 30° C. to about 60° C. The resulting pea protein hydrolysate has a solubility of at least 30% at pH 3.4, a viscosity of at least 65 cPs at pH 3.4, a dispersibility of at least 115 seconds at about neutral pH, and a suspendability of at least 1.5 TSI Global at pH 3.4.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: November 12, 2024
    Assignee: CARGILL, INCORPORATED
    Inventors: Sonia Han, Pam Ismail, Paige Ties, Rachel Mitacek
  • Patent number: 12128130
    Abstract: The present invention relates to an injectable pharmaceutical composition containing keratin for preventing hair loss or stimulating hair growth, wherein the composition is excellent in hair follicle generating and hair growth stimulating effects, and thus can be favorably used as a preventive and therapeutic agent for hair loss or a stimulating agent for hair growth.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: October 29, 2024
    Assignee: KERAMEDIX INC.
    Inventors: Yu-Shik Hwang, Il-Keun Kwon, So Yeon Kim, Se Young Van
  • Patent number: 12130291
    Abstract: Kits and methods of using the kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and/or nucleic acid recording of a molecular interaction and/or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Additional barcoding reagents, such as those for cycle-specific barcoding (e.g., “clocking”), compartment barcoding, combinatorial barcoding, spatial barcoding, or any combination thereof, may be included in the kits. The sample may comprise macromolecules, including peptides, polypeptides, and proteins, and the recording may generate molecular interaction and/or reaction information, and/or polypeptide sequence information.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: October 29, 2024
    Assignee: Encodia, Inc.
    Inventors: Mark S. Chee, John M. Beierle, Norihito Muranaka, Kevin L. Gunderson, Michael Phillip Weiner, Lei Shi, Robert C. James, Luca Monfregola
  • Patent number: 12115356
    Abstract: The invention relates to a dispenser of a sealant for hemostasis comprising a container configured to receive a fibrinogen solution and an activation compartment being situated downstream of the container and comprising a functionalized support to which a coagulation factor, preferably thrombin, is immobilized, such that upon dispensing the fibrinogen solution it passes through the activation compartment, thereby generating and dispensing polymerizing fibrin as a sealant. The invention further relates to a support, exchangeable tip and a kit for the dispenser as well as to methods and uses of the dispenser or components thereof for dispensing a sealant to a desired site.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: October 15, 2024
    Assignee: GAMBRO LUNDIA AB
    Inventors: Jan Swartjes, Stefanie Votteler, Markus Storr, Bernd Krause
  • Patent number: 12102615
    Abstract: The subject invention pertains to methods for producing novel occidiofungin analogues lacking xylose (OF-?xyl analogue). OF-?xyl analogues can contain aldehyde, amine, triazole, or hydrazones. The aldehyde, amine, triazole or hydrazone containing analogues of OF-?xyl can be further modified by substitution with additional functional groups. Various OF-?xyl analogues described herein have reduced inflammation and toxicity and superior pharmacological properties compared to the natural occidiofungins. Accordingly, certain embodiments of the invention provide methods of treating or preventing fungal infections by administering to the subjects in need thereof the OF-?xyl analogues described herein.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: October 1, 2024
    Assignees: THE TEXAS A&M UNIVERSITY SYSTEM, SANO CHEMICALS
    Inventors: James L. Smith, Mengxin Geng, Akshaya Ravichandran, Ravi Orugunty
  • Patent number: 12091695
    Abstract: The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: September 17, 2024
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Henry M. Colecraft, Scott Kanner
  • Patent number: 12091391
    Abstract: Tetrazine non-canonical amino acids, methods for genetic encoding proteins and polypeptides using the tetrazine amino acids, proteins and polypeptides comprising the tetrazine amino acids, and compositions comprising the proteins and polypeptides having at least one post-translational modification thereof comprising in vivo reaction with the incorporated tetrazine amino acid and a second molecule.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: September 17, 2024
    Assignee: Oregon State University
    Inventors: Ryan A. Mehl, Robert Blizzard
  • Patent number: 12084574
    Abstract: Provided is a flexible polyurethane foam having high hardness required for weight reduction of members and having low stress relaxation. A flexible polyurethane foam comprises a structural protein fiber having a length of 0.1 mm to 5 mm.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: September 10, 2024
    Assignees: BRIDGESTONE CORPORATION, Spiber Inc.
    Inventors: Koji Sanefuji, Hideharu Seguchi, Toshiki Takizawa, Naoko Nisikita
  • Patent number: 12085577
    Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: September 10, 2024
    Assignee: Cleveland Heartlab, Inc.
    Inventors: Timothy Collier, Cory Bystrom, Angela Higgins
  • Patent number: 12084696
    Abstract: The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: September 10, 2024
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Henry M. Colecraft, Scott Kanner
  • Patent number: 12071459
    Abstract: The present invention relates to a field of biotechnology. It discloses a novel amino acid sequence of recombinant human bone morphogenetic protein-2 (rhBMP-2) and encoded nucleotide sequences thereof, and a method for preparing rhBMP-2. In the present invention, by further optimizing the nucleotide sequence of rhBMP-2, novel amino acid sequence of rhBMP-2 that can express good ectopic induced osteogenic activity and has good renaturation and purification effect is screened out. The engineered bacteria constructed by the present invention can induce the production of recombinant rhBMP-2 protein with an expression level of about 55%, and the produced target protein is more easily denatured and purified than the existing recombinant rhBMP-2, with better denaturation and purification effect and higher osteoinductive activity.
    Type: Grant
    Filed: April 10, 2022
    Date of Patent: August 27, 2024
    Assignee: ZHEJIANG RISING BIOTECHNOLOGY CO., LTD.
    Inventor: Jianxin Cao
  • Patent number: 11986004
    Abstract: Food-grade pulse protein concentrates prepared from various pulses and flours derived therefrom are provided. Also provided are method of making the concentrates and beverages and foodstuffs that include the concentrates. The pulse protein concentrates are characterized by a high protein content, high digestibility, and complete essential amino acid profile.
    Type: Grant
    Filed: February 14, 2023
    Date of Patent: May 21, 2024
    Assignee: Innovative Proteins Holding, LLC
    Inventors: Seth A. Foster, Tim G. Foster, Donald L. Crank
  • Patent number: 11976107
    Abstract: The invention comprises several embodiments of a multi-step method for processing hard tissues, including bone, teeth, tooth enamel and dentin, mollusk shells, crustacean shells, deep sea sponge, coral, radiolarians, diatoms, antler bone, and other naturally occurring mineralized biocomposites, and soft tissues, including connective tissue, cartilage, tendon, ligament, vertebral discs, pathological mineralized soft tissues and other soft tissues, including at least processing a portion of tissue by one or more of contacting, immersing, adding and mixing a portion of tissue with a first solution, obtaining a first material, derived from processing the portion of tissue with the first solution, processing the first material using one or more alkali metal and ammonium salts of citrate, acetate, phosphate, sulfate, tartarate and chloride, and obtaining a resulting material, derived from processing the first material with the one or more salts.
    Type: Grant
    Filed: January 10, 2021
    Date of Patent: May 7, 2024
    Assignee: ORTHOGRAFT PRIVATE LIMITED
    Inventor: Atharva Poundarik
  • Patent number: 11965032
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: February 10, 2023
    Date of Patent: April 23, 2024
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Patent number: 11918007
    Abstract: The present disclosure relates to a foodstuff composition, in particular a spreadable food composition, more in particular an olive oil-based functional spread fat composed by olive oil fortified with a functional ingredient—the olive pomace active ingredient. This functional ingredient is a mixture of bioactive compounds, in particular hydroxytyrosol, tyrosol, sterols, tocopherols, triterpenes, coenzyme Q10, K, Mg and Ca, among others, obtained from olive pomace by mechanical pressing.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: March 5, 2024
    Assignee: UNIVERSIDADE DO PORTO
    Inventors: Maria Beatriz Prior Pinto Oliveira, Maria Antónia Da Mota Nunes, Anabela Sílvia Guedes Da Costa
  • Patent number: 11913922
    Abstract: Techniques and apparatus for performing target compound detection processes are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured to implement a targeted compound detection process, for example, by receiving raw data from analysis of a sample via an analytical device, generating cumulative data from the raw data, receiving compound specification information associated with the sample, and determining quantified compound information via performing targeted compound detection based on the cumulative data and the compound specification information to determine. Other embodiments are described.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: February 27, 2024
    Assignee: WATERS TECHNOLOGIES IRELAND LIMITED
    Inventors: Ian Morns, Jackson Pope, Wilka Hudson
  • Patent number: 11891645
    Abstract: The present invention relates to serine protease variants, having improved properties compared to the parent protease, in particular variants of a serine protease derived from a strain of Meripilus giganteus belonging to the S53 family. The varinats according to the invention have in particular increased stability, e.g., increased thermo-stability, increased specific activity, and/or increased expression levels, compared to the parent protease. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: February 6, 2024
    Assignee: NOVOZYMES A/S
    Inventors: Dorte M. K. Klitgaard, Roland Alexander Pache, Martin Gudman, Anders G. Sandström
  • Patent number: 11872215
    Abstract: Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 16, 2024
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Geert-Jan Boons
  • Patent number: 11807689
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: November 7, 2023
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Patent number: 11808675
    Abstract: Reagents and methods for extracting and stabilizing metabolites at room temperature and methods in which metabolites and one or more of proteins, lipids and nucleic acids are extracted from a single sample in a unified workflow.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: November 7, 2023
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Genevieve Van de Bittner, James Alexander Apffel, Steven M. Fischer, Christine A. Miller, Kristin Briana Bernick
  • Patent number: 11786477
    Abstract: Disclosed herein are low density particles comprising polymerized fibrin that are micrometer or nanometer sized in diameter. The particles can further include at least one therapeutic agent. The particles may be used to treat wounds, by administration directly or systemically to the site of the wound. Exemplary wounds that may be treated with the fibrin particles include a trauma wound, a surgical wound, a burn wound, or an ulcer wound. Also disclosed herein are methods for preparing the particles using a shearing process.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: October 17, 2023
    Assignee: North Carolina State University
    Inventors: Ismaeel Muhamed, Ashley C. Brown, Frances S. Ligler
  • Patent number: 11766483
    Abstract: The invention relates to novel compounds with the ability to link an immune response to a defined therapeutic target, to the use of said compounds in treating cancer and infectious diseases, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: September 26, 2023
    Assignee: CENTAURI THERAPEUTICS LIMITED (GB/GB)
    Inventors: Michael Westby, Melanie Glossop, Christine Watson, Christopher Pickford
  • Patent number: 11752200
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: September 12, 2023
    Assignee: EnClear Therapies Inc.
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Patent number: 11746374
    Abstract: Disclosed herein are methods and platforms using Receptor Compartmentalized Partnered Replication (CPR), in which the partner gene is a receptor, signal transduction pathway, or metabolic pathway that leads to the production of an effector molecule for the receptor or signal transduction pathway. The signal transduction pathway or receptor is coupled to the production of a thermostable polymerase. Emulsification of libraries of organisms with primers that can amplify the partner gene led to the selective amplification of those partner genes that were best able to produce the thermostable polymerase during thermal cycling of the emulsion.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: September 5, 2023
    Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE TEXAS A&M UNIVERSITY
    Inventors: Andrew Ellington, Jimmy Gollihar, Katy Kao, Elizabeth Gardner
  • Patent number: 11724414
    Abstract: A defibrated material manufacturing device is configured to defibrate a feedstock of clumps of shreds containing fiber into defibrated material. The defibrated material manufacturing device has a removal device, a metering device, storage device, and a defibrator. The removal device is configured to remove at least a part of foreign matter contained in the feedstock. The metering device is configured to measure the feedstock that has passed the removal device. The storage device is configured to store a measured feedstock measured by the metering device. The defibrator is configured to defibrate the measured feedstock supplied from the storage device into the defibrated material.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 15, 2023
    Assignee: Seiko Epson Corporation
    Inventor: Yoichi Miyasaka
  • Patent number: 11723983
    Abstract: The invention relates to a glycoprotein-toxic pay-load molecule conjugate, a toxic payload molecule-glycan conjugate, and a pharmaceutical composi-tion. The invention further relates to a method for preparing the glycoprotein-toxic payload molecule conjugate, the method for modulating growth of a cell population and a method of treating tu-mour cells.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: August 15, 2023
    Assignee: GLYKOS FINLAND OY
    Inventors: Tero Satomaa, Jari Helin, Filip S. Ekholm
  • Patent number: 11692983
    Abstract: The present invention provides reagents for instrumentation quality control and methods of use thereof. In particular, sets of peptides or other molecules are provided for evaluating the performance of instruments with mass spectrometry (MS) and/or liquid chromatography (LC) functionalities.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: July 4, 2023
    Assignee: Promega Corporation
    Inventors: Joshua Jacques Coon, Michael M. Rosenblatt, Marjeta Urh
  • Patent number: 11655279
    Abstract: The present invention relates to a method for producing an active form of a long-acting insulin analogue derivative, in which the amino acid at position 22 of the insulin B-chain is substituted from arginine (Arg) to lysine (Lys), so that the insulin analogue can be converted to an active form without cleavage of the B-chain even when it is reacted with clostripain. In a conventional method of converting pro-insulin to an active form by use of trypsin, an albumin binding domain is cleaved, making it difficult to convert the long-acting insulin analogue derivative to an active form. The production method according to the present invention overcomes this difficulty, and thus it can be effectively used for the production of a long-acting therapeutic agent for treatment of diabetes.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: May 23, 2023
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Kyong Hoon Ahn, Seonkyeong Jeong, Chaeha Yoon
  • Patent number: 11641869
    Abstract: Food-grade pulse protein concentrates prepared from various pulses and flours derived therefrom are provided. Also provided are method of making the concentrates and beverages and foodstuffs that include the concentrates. The pulse protein concentrates are characterized by a high protein content, high digestibility, and complete essential amino acid profile.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: May 9, 2023
    Assignee: Innovative Proteins Holding, LLC
    Inventors: Seth A. Foster, Tim G. Foster, Donald L. Crank
  • Patent number: 11639514
    Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: May 2, 2023
    Assignee: Leidos, Inc.
    Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
  • Patent number: 11634512
    Abstract: The present invention is directed to a polymer of Formula (IV): wherein A, X, Q, Y, Z, m1; m2, m3, k1; and k2 are as described herein and wherein the monomer units of the polymer are the same or different. The present invention also relates to a monomer of Formula (III), wherein R?, X1, Y1, Z1, m4, m5, and m6 are as described herein, and a polymeric network comprising two or more monomers of Formula (III). The present invention also relates to a hydrogel comprising any of the polymers and monomers described herein, a capsule comprising the hydrogel, and a method of delivering a therapeutic agent to a subject using the capsule.
    Type: Grant
    Filed: January 27, 2018
    Date of Patent: April 25, 2023
    Assignee: CORNELL UNIVERSITY
    Inventors: Minglin Ma, Qingsheng Liu
  • Patent number: 11628225
    Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): a pharmaceutically acceptable salt thereof wherein Ab is an antibody without glycans (i.e., the protein portion an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2; are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: April 18, 2023
    Assignee: CHO PHARMA INC.
    Inventors: Nan-Horng Lin, Charng-Sheng Tsai, Ting-Chun Hung, Hong-Yang Chuang
  • Patent number: 11608363
    Abstract: The present disclosure provides materials and methods for cell-free expression of epitopes for immunotherapy applications. In particular, the present disclosure provides materials and methods for expressing concatenated epitopes using a cell-free protein synthesis platform for high throughput, large scale, and unbiased epitope screening and the generation of multi-epitope vaccines.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: March 21, 2023
    Assignee: Leidos, Inc
    Inventors: Stephen A. Chappell, Vincent P. Mauro, John Dresios
  • Patent number: 11559587
    Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: January 24, 2023
    Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SE
    Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
  • Patent number: 11538558
    Abstract: Gene sequences are tailored for protein expression by measuring ribosome dynamics, training a statistical model of the relationship between DNA sequence and translation speed; and using this model to design an optimal DNA sequence encoding a given protein.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 27, 2022
    Assignee: The Regents of the University of California
    Inventors: Liana Faye Lareau, Robert Tunney
  • Patent number: 11530381
    Abstract: The present invention describes methods for quantifying and analyzing cell migration and drug screening. Such methods include a gel (or a hydrogel) comprising a polymer, and cells that forms an oxygen gradient within the gel by controlling the balance of the diffusion of oxygen through the top of the gel and by the consumption of oxygen uptake by the cells. The migration of the cells is determined while the cells are grown in the gel of the present invention.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: December 20, 2022
    Assignees: The Johns Hopkins University, The Trustees of the University of Pennsylvania
    Inventors: Sharon Gerecht, Daniel Lewis, Kyung Min Park, T. S. Karin Eisinger, M. Celeste Simon
  • Patent number: 11524977
    Abstract: An ultrasound-assisted simulated digestion method of a milk protein active peptide and an application thereof in health foods, pertaining to the technical field of intensive processing of dairy products and preparation of health foods. The method firstly employs ultrasonic pretreatment of casein and ?-lactoglobulin, followed by enzymatic hydrolysis with a protease to prepare casein and ?-lactoglobulin polypeptide, and traces the activity of the polypeptide by simulating gastrointestinal digestion, and then simulates absorption by intestinal epithelial cells with Caco-2 cells, to characterize a highly active milk protein polypeptide digested by the gastrointestinal tract and absorbed by the Caco-2 cells simulating absorption by the inner wall of the small intestine. The method has identified five such highly active milk protein polypeptides.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: December 13, 2022
    Assignee: JIANGSU UNIVERSITY
    Inventors: Xiaofeng Ren, Qiufang Liang, Haile Ma, Yuqing Duan, Ronghai He, Xiaoming Yang, Xi Zhang, Ting Hou, Xinxiang Chen
  • Patent number: 11518988
    Abstract: The present invention relates to polypeptide variants of porcine trypsin, to nucleic acid molecules encoding these variants, and to host cells comprising such nucleic acid molecules. It also relates to the use of these variants in methods for producing insulin. The invention further relates to the use of these variants as medicaments, as food ingredients, or as feed ingredients and to the use of these variants within a process of manufacturing a food ingredient or a feed ingredient.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 6, 2022
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Thomas Stillger, Sebastian Rissom, Claudia Feller, Andreas Vogel
  • Patent number: 11504386
    Abstract: The present invention relates to a preparation method for various novel fucosyl oligosaccharides and a use thereof. More specifically, the present invention allows a preparation of various novel fucosyl oligosaccharides through an enzymatic reaction with ?-1,2-fucosyltransferase using a GDP-L-fucose donor and various glucose acceptors and an establishment of probiotic characteristics thereof, and thus has an effect of providing uses as materials for medicines, food, cosmetic products, and the like.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 22, 2022
    Assignee: Korea University Research and Business Foundation
    Inventors: Kyoung Heon Kim, Yong-Su Jin, Eun-Ju Yun, Sora Yu, Jaewon Lee
  • Patent number: 11492654
    Abstract: Disclosed is a method of measuring protein kinase activity, including a) attaching GMBS (N-[?-maleimidobutyryloxy]sulfosuccinimide ester) to a base plate, b) attaching a substrate that reacts with a protein kinase to the base plate having GMBS attached thereto, thus manufacturing a kit for measuring protein kinase activity, c) introducing, to the kit, a mixture of a sample to be analyzed and a buffer including triton X-100, and d) probing phosphorylation of the substrate caused by the protein kinase contained in the sample, thereby measuring the activity of the protein kinase.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: November 8, 2022
    Assignees: Kangwon National University University-industry Cooperation Foundation, AMOLIFESCIENCE CO., LTD.
    Inventors: Kwon-Soo Ha, Deok-Hoon Kong
  • Patent number: 11408022
    Abstract: A method of preparing an anti-oxidation polypeptide having an amino acid sequence of SEQ ID NO:1 includes enzymatic hydrolysis of black shark skins, which serve as the raw material, with alkali protease, separation, purification, freezing, and drying to obtain the anti-oxidation polypeptide. Enzymatic hydrolysis conditions include 7.0-9.0 pH value, 40-50° C. temperature, 4.0-6.0 h enzymatic hydrolysis time, 2.0-4.0% primer concentration, and 9.0-10.0 wt % of enzymes.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: August 9, 2022
    Assignee: FU ZHOU UNIVERSITY
    Inventors: Shaoyun Wang, Xixi Cai, Qingyan He, Ana Yan, Qianwen Ye
  • Patent number: 11389511
    Abstract: The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: July 19, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen